Navigation Links
Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
Date:11/13/2008

ize genotyping in cytology negative, HPV-positive women in the same manner as high-risk HPV testing is utilized in women with ASC-US." If regulatory approvals for the Cervista 16/18 test are obtained, Hologic will be well positioned to work with professional societies, physicians and laboratories to address the needs of this group of women.

The results of these clinical trials combined with the other attributes of the test should allow Hologic to compete in the rapidly growing HPV testing market both in the U.S. and internationally. The Cervista HPV high-risk test is currently under review by the FDA in the U.S. Hologic has obtained CE marking of the Cervista HPV test and is currently in the final stages of obtaining CE Mark approval for the sample preparation component of the test. The company expects to launch the product in the EU in January 2009.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications. For more information, visit http://www.hologic.com.

Forward-Looking Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the effect and adoption of the use of the Cervista HPV testing products. There can be no assurance that the tests will ach
'/>"/>

SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
2. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
3. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
6. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Immunosyn Corporation Releases SF-1019 Study Results
11. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- MedSolutions ( www.medsolutions.com ), a leading provider ... new studies highlighting the dangers of excess radiation ... tests. ,, "When used properly, CT imaging ... Gregg Allen, M.D., chief medical officer of MedSolutions. ... that stricter quality control measures are necessary to ...
(Date:12/16/2009)... Ohio, Dec. 16 HDT Engineered Technologies ... generation technologies and a principal subcontractor for the ... led development of new anthropromorphic arm technology that ... prosthetic arm and hand, including a sense of ... Advanced Research Projects Agency (DARPA) Revolutionizing Prosthetics 2009 ...
(Date:12/16/2009)... 16 Ethicon, Inc., a Johnson & ... a worldwide leader in surgical care, and Acclarent, ... to designing, developing and commercializing devices that address ... today announced a definitive merger agreement whereby Ethicon ... approximately $785 million net of estimated cash on ...
Breaking Medicine Technology:MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 15025 1Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 15025 2Neogen Acquires Gen Probes BioKits Food Safety Business 6639 1Neogen Acquires Gen Probes BioKits Food Safety Business 6639 2BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 6637 1BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 6637 2BioInformatics LLC New Report The Market Outlook for Research Products in FY2010 6637 3
... Mass., Aug. 14 StatSure,Diagnostic Systems, Inc. (OTC Bulletin ... patented, "barrel- test" format for the detection of,antibodies to ... completed,the trials needed for a CLIA waiver application and ... Food & Drug Administration (FDA) for,their review. The Company ...
... Efficacy of LBH589 in ... Myeloma, NORWALK, Conn., Aug. 14 The Multiple ... Phase II,study to determine the efficacy of LBH589 for ... LBH589 is an orally,administered deacetylase inhibitor developed by Novartis ...
Other Medicine Technology:CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 2CLIA Waiver Submitted for Rapid HIV Test Employs StatSure's 'Barrel' Technology 3Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor 2Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor 3
(Date:12/16/2009)... CHICAGO, Dec. 16 Allscripts (Nasdaq: ... its financial results for the three and six ... market opens on Monday, January 11, 2010. Allscripts ... to discuss the company,s earnings and other information ... morning. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, ...
(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...
(Date:12/16/2009)... to disease , , WEDNESDAY, Dec. 16 (HealthDay News) ... leprosy have been identified by scientists in Singapore ... than 10,000 DNA samples from leprosy patients and ... the important role that the innate immune response ... leprosy is not common, the discoveries have significant ...
(Date:12/16/2009)... and environmental concerns about the emerging nanotechnology industry, scientists ... of nanoparticles in municipal sewage treatment plants their ... in ACS, journal Environmental Science & Technology . ... and Hydrology and colleagues note that experts predict large ... than 1/1000th the width of a human hair ...
(Date:12/16/2009)... Episencial Offers Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging at ... ... Los Angeles, CA (PRWEB) December 16, 2009 -- Actively ... choice in all natural skin care for their children as ... young children featuring the beloved artwork of The Very Hungry ...
Breaking Medicine News(10 mins):Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:Leprosy Genes Identified 2Health News:Behavior modification could ease concerns about nanoparticles 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5
... its continued commitment to providing high-quality information to ... the prestigious journal Advances in Therapy, to be ... enhances its services for clients in the pharmaceutical, ... in Therapy, to be published by Springer Healthcare ...
... Another Scientific ... ... Association, DENVER, Oct. 31 "The WCRF/AICR recommendations about,red meat and cancer are ... of red meat in a healthy,diet that far outweigh anything we,ve seen today. ...
... in October is partly seasonal * ... regions post no over the year gains in advertised ... ... NEW YORK, Oct. 31 In October there were 4,161,700,online advertised vacancies, ...
... have a strong tropism for hepatocytes; viral antigen also ... is common in Fulminant hepatic failure but rarely reported ... viral hepatitis over a three year period were involved. ... had acute pancreatitis and 17 had stretching of glissons ...
... Calif., Oct. 31 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... $2.1 million from Merz Pharmaceuticals GmbH (Merz) for ... for the treatment of,moderate-to- severe Alzheimer,s disease for ... 27% increase in NTI,s royalty payments compared to,the ...
... Mass., Oct. 31 Biopure Corporation,(Nasdaq: BPUR ) ... A,common stock will revert from BPURD to BPUR at ... Outstanding warrants that trade on the OTCBB,will revert to ... to BPURZ; and BPREL reverting to BPURL. Biopure ...
Other Medicine News:Health News:NCBA Statement on 2007 WCRF/AICR Second Expert Report on Food, Nutrition and Physical Activity and the Prevention of Cancer: 2Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 2Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 3Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 4Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 5Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 6Health News:Is it pancreatitis in acute abdominal pain in acute viral hepatitis? 2Health News:Biopure's Stock Symbol Reverts to BPUR 2
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... Type 300 ,Oblique 45, ,Type 330 ... illumination by setting the illumination between ... be ideal for use in ophthalmology ... other conventional compact microscope can; an ...
... is exactly the same as the model SP-8800 with ... separate Pachy mode. This mode has its own fixation ... all directions. It allows you to select an area ... has built-in software to calculate averages of multiple readings ...
... MedCath is the largest and most experienced ... networks in the United States. Mobile laboratories ... a daily basis, from one hospital to ... geographic area. Each mobile laboratory is fully ...
Medicine Products: